A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Dermatitis, Atopic by LEO Pharma — 1 open to participants now, 1 under way, 1 of them phase 3. Dermatitis, Atopic · LEO Pharma.
Among the 36 studies in Dermatitis, Atopic by LEO Pharma, this one is the 8th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2018, is one of 8 in phase 2, and was the 25th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 36 studies in Dermatitis, Atopic by LEO Pharma is open now, in 12 countries. Recruiting first, the newest first:
LEO Pharma · Sites in United States, Belgium, Canada and 10 more countries
Ages 6 mo–11 yrs
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 70 across the 34 interventional studies, 4,063 across the 2 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Dermatitis, Atopic by LEO Pharma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Delgocitinib cream applied twice daily for 8 weeks
Drug: Delgocitinib cream
Delgocitinib cream applied twice daily for 8 weeks
Drug: Delgocitinib cream
Delgocitinib cream applied twice daily for 8 weeks
Drug: Delgocitinib cream
Delgocitinib cream applied twice daily for 8 weeks
Drug: Delgocitinib cream
Delgocitinib cream vehicle applied twice daily for 8 weeks
Drug: Delgocitinib cream vehicle
Cream for topical application
Also known as: LEO 124249 cream
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Also known as: LEO 124249 cream vehicle
Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.
EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Mixed Model for Repeated Measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib doses and delgocitinib cream vehicle.
Time frame: Week 0 to Week 8
Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of 0 (Clear) or 1 (Almost Clear) With ≥2-step Improvement (vIGA-AD TS) From Baseline to Week 8.
vIGA-AD is an instrument used in clinical trials to assess the subject's global disease severity and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose-selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and the delgocitinib cream vehicle.
Time frame: Week 0 to Week 8
EASI75 at Week 8
EASI75 is defined as at least 75% reduction in EASI from baseline.
Time frame: Week 0 to Week 8
Time to vIGA-AD TS
The time to vIGA-AD TS response is defined as the time from baseline to first assessment of a vIGA-AD score of 0 (Clear) or 1 (Almost Clear) with ≥2-step improvement
Time frame: Week 0 to Week 8
251 participants from 31 sites in 3 countries (U.S., Canada and Australia) were randomised in this trial. The first participant was screened on 29-Nov-2018 and the last participant completed the trial on 19-May-2020.
| Milestone | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Started | 49 | 50 | 50 | 52 | 50 |
| Completed | 38 | 44 | 44 | 46 | 36 |
| Not completed | 11 | 6 | 6 | 6 | 14 |
| Withdrew: Lack of efficacy | 2 | 1 | 2 | 0 | 2 |
| Withdrew: Adverse event | 2 | 2 | 1 | 0 | 6 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 | 4 | 4 |
| Withdrew: Lost to follow-up | 3 | 1 | 2 | 2 | 1 |
| Withdrew: Personal reasons | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Covid-19 situation | 0 | 1 | 0 | 0 | 0 |
EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Mixed Model for Repeated Measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib doses and delgocitinib cream vehicle.
| score on a scale | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score. | -5.0 ± 0.7 | -4.9 ± 0.7 | -5.8 ± 0.7 | -7.6 ± 0.7 | -1.9 ± 0.8 |
vIGA-AD is an instrument used in clinical trials to assess the subject's global disease severity and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose-selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and the delgocitinib cream vehicle.
| Participants | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of 0 (Clear) or 1 (Almost Clear) With ≥2-step Improvement (vIGA-AD TS) From Baseline to Week 8. | 9 | 14 | 15 | 24 | 5 |
EASI75 is defined as at least 75% reduction in EASI from baseline.
| Participants | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| EASI75 at Week 8 | 20 | 21 | 28 | 33 | 10 |
The time to vIGA-AD TS response is defined as the time from baseline to first assessment of a vIGA-AD score of 0 (Clear) or 1 (Almost Clear) with ≥2-step improvement
| Days | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Time to vIGA-AD TS | 64 (42 to 64) | NA (42 to NA) | 64 (28 to 64) | 44 (26 to NA) | NA (56 to NA) |
Collected over 10 weeks (from first application of IMP up until the last visit (safety follow-up visit)).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delgocitinib Cream 1 mg/g | 0/49 (0%) | 1/49 (2%) | 12/49 (24.5%) |
| Delgocitinib Cream 3 mg/g | 0/50 (0%) | 1/50 (2%) | 11/50 (22%) |
| Delgocitinib Cream 8 mg/g | 0/50 (0%) | 0/50 (0%) | 8/50 (16%) |
| Delgocitinib Cream 20 mg/g | 0/51 (0%) | 0/51 (0%) | 12/51 (23.5%) |
| Delgocitinib Cream Vehicle | 0/50 (0%) | 1/50 (2%) | 11/50 (22%) |
| Event | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/49 | 0/50 | 0/50 | 0/51 | 0/50 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/49 | 0/50 | 0/50 | 0/51 | 1/50 |
| Hypertonic bladderRenal and urinary disorders | 0/49 | 1/50 | 0/50 | 0/51 | 0/50 |
| Event | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/49 | 3/50 | 6/50 | 6/51 | 4/50 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 5/49 | 2/50 | 1/50 | 2/51 | 3/50 |
| AcneSkin and subcutaneous tissue disorders | 0/49 | 4/50 | 0/50 | 1/51 | 0/50 |
| Application site pruritusGeneral disorders | 0/49 | 1/50 | 1/50 | 0/51 | 3/50 |
| HeadacheNervous system disorders | 2/49 | 1/50 | 1/50 | 3/51 | 1/50 |
Number of subjects randomized
| Age, Continuous(years) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Mean | 43.8 ± 16.1 | 38.5 ± 16.6 | 42.0 ± 17.4 | 37.4 ± 14.7 | 41.3 ± 19.6 | 40.5 ± 17.0 |
| Sex: Female, Male(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Female | 34 | 33 | 32 | 37 | 36 | 172 |
| Male | 15 | 17 | 18 | 15 | 14 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 5 | 8 | 1 | 25 |
| Not Hispanic or Latino | 44 | 44 | 45 | 44 | 49 | 226 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| White | 27 | 28 | 23 | 28 | 26 | 132 |
| Black or African American | 3 | 11 | 5 | 4 | 8 | 31 |
| Asian | 12 | 9 | 19 | 15 | 14 | 69 |
| Native Hawaiian or other Pacific islander | 0 | 0 | 0 | 0 | 1 | 1 |
| American Indian or Alaska native | 0 | 0 | 0 | 1 | 0 | 1 |
| Other | 7 | 2 | 3 | 4 | 1 | 17 |
| Region of Enrollment(participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Canada | 15 | 9 | 19 | 15 | 14 | 72 |
| United States | 23 | 29 | 19 | 24 | 25 | 120 |
| Australia | 11 | 12 | 12 | 13 | 11 | 59 |
| Baseline EASI score(units on a scale) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Mean | 9.3 ± 5.2 | 10.9 ± 9.1 | 8.6 ± 4.6 | 9.9 ± 6.9 | 11.2 ± 7.3 | 10.0 ± 6.8 |
| Baseline vIGA-AD score(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 - Almost clear | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 - Mild | 18 | 18 | 18 | 19 | 17 | 90 |
| 3 - Moderate | 27 | 28 | 28 | 28 | 29 | 140 |
| 4 - Severe | 4 | 4 | 4 | 5 | 4 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in May 2020, 16 months.
Results were first posted in Jul 2021, 1 year 1 month after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib